Physician profile
Faisal B Saiful
NPI 1205081494
$33,175.98
in general payments reported to CMS, 2019-2025
39 companies · $3,582 in 2025
The $3,582 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $13K · 2021: $3,548 · 2022: $5,871 · 2023: $4,202 · 2024: $1,843 · 2025: $3,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,583 · Travel and Lodging: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,582.90 |
| Travel and Lodging | $1,043.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $10,687.82 | 2019-2020 | |
| Edwards Lifesciences Corporation | $7,368.16 | 2020-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $4,232.21 | 2019-2025 | Triclip, Diamondback Peripheral, Mitraclip |
| Boston Scientific Corporation | $1,170.21 | 2020-2024 | Watchman Access System, Opticross |
| Aop Health US, LLC | $1,045.76 | 2025 | Rapiblyk |
| Medtronic, INC. | $1,007.31 | 2021-2025 | Micra, Corevalve Evolut R, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $618.10 | 2019-2025 | |
| Shockwave Medical, INC | $597.13 | 2019-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $537.20 | 2019-2024 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $509.48 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $505.13 | 2019-2025 | Farxiga, Wainua |
| Pfizer INC. | $471.84 | 2019-2025 | |
| Amgen INC. | $460.27 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $438.80 | 2019-2022 | |
| Abiomed | $412.91 | 2022-2025 | Impella |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Saiful listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.